Related Experiment Video

Updated: Jul 5, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Advances in the treatment of non-small cell lung cancer

Nagahiro Saijo1

  • 1National Cancer Center, Hospital East, Kashiwanoha 6-5-1, Kashiwa-shi, Chiba 277-8577, Japan. nsaijo@east.ncc.go.jp

Cancer Treatment Reviews
|May 27, 2008
PubMed

Insights

Lung cancer treatment lags behind other cancers. Identifying specific molecular biomarkers is crucial for effective targeted therapies and improving patient outcomes through carefully selected patient populations in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Lung cancer treatment advances have been marginal compared to breast, colorectal, and genitourinary cancers.
  • Developing new standard treatments for lung cancer remains challenging.

Purpose of the Study:

  • To highlight the difficulties in evaluating molecularly targeted drugs in unselected lung cancer patient populations.
  • To emphasize the need for identifying specific molecular biomarkers for each targeted drug.
  • To advocate for sophisticated clinical trials in selected patient populations to improve lung cancer treatment outcomes.

Main Methods:

  • Review of clinical trial results for gefitinib and erlotinib.
  • Analysis of challenges in evaluating molecularly targeted drugs versus cytotoxic drugs.
  • Discussion on the importance of patient selection and biomarker identification.

Main Results:

  • Evaluation of molecularly targeted drugs in unselected patient populations is difficult and differs from cytotoxic drugs.
  • Specific molecular biomarkers are essential for the effective use of targeted therapies.
  • Sophisticated clinical trials in selected populations are needed for significant improvements.

Conclusions:

  • Targeted lung cancer therapies require precise patient selection based on molecular biomarkers.
  • Future research must focus on identifying these biomarkers and conducting well-designed clinical trials.
  • Improved treatment strategies are essential to enhance outcomes for lung cancer patients.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...